AstraZeneca (NASDAQ:AZN – Get Rating) had its price objective cut by equities researchers at Argus from $85.00 to $80.00 in a research report issued to clients and investors on Friday, The Fly reports. Argus’ target price would indicate a potential upside of 10.25% from the stock’s current price.
AZN has been the subject of a number of other research reports. StockNews.com started coverage on shares of AstraZeneca in a report on Thursday, May 18th. They set a “strong-buy” rating for the company. Morgan Stanley raised shares of AstraZeneca from an “equal weight” rating to an “overweight” rating in a report on Tuesday, April 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Moderate Buy” and an average price target of $103.00.
AstraZeneca Stock Performance
AZN opened at $72.56 on Friday. The stock has a market cap of $224.91 billion, a P/E ratio of 47.23, a P/E/G ratio of 1.45 and a beta of 0.52. The firm has a fifty day moving average price of $73.83 and a 200 day moving average price of $69.02. The company has a debt-to-equity ratio of 0.75, a current ratio of 0.90 and a quick ratio of 0.70. AstraZeneca has a 1 year low of $52.65 and a 1 year high of $76.56.
Institutional Investors Weigh In On AstraZeneca
AstraZeneca Company Profile
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.